160 related articles for article (PubMed ID: 26022261)
1. Neurokinin-1 (NK₁) receptor antagonists as possible therapeutics for psychostimulant use disorders.
Olive MF
CNS Neurol Disord Drug Targets; 2015; 14(6):700-6. PubMed ID: 26022261
[TBL] [Abstract][Full Text] [Related]
2. The tachykinin NK1 receptor in the brain: pharmacology and putative functions.
Saria A
Eur J Pharmacol; 1999 Jun; 375(1-3):51-60. PubMed ID: 10443564
[TBL] [Abstract][Full Text] [Related]
3. Contractile effect of tachykinins on Suncus murinus (house musk shrew) isolated ileum.
Cheng FH; Chan SW; Rudd JA
Neuropeptides; 2008; 42(5-6):671-9. PubMed ID: 18582934
[TBL] [Abstract][Full Text] [Related]
4. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
[TBL] [Abstract][Full Text] [Related]
5. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
6. Identification of both NK1 and NK2 receptors in guinea-pig airways.
McKee KT; Millar L; Rodger IW; Metters KM
Br J Pharmacol; 1993 Oct; 110(2):693-700. PubMed ID: 7694756
[TBL] [Abstract][Full Text] [Related]
7. Substance P and the Neurokinin-1 Receptor: The New CRF.
Schank JR; Heilig M
Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
[TBL] [Abstract][Full Text] [Related]
8. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice.
Teixeira RM; Santos AR; Ribeiro SJ; Calixto JB; Rae GA; De Lima TC
Eur J Pharmacol; 1996 Sep; 311(1):7-14. PubMed ID: 8884230
[TBL] [Abstract][Full Text] [Related]
9. The new neurokinin 1-sensitive receptor mediates the facilitation by endogenous tachykinins of the NMDA-evoked release of acetylcholine after suppression of dopaminergic transmission in the matrix of the rat striatum.
Kemel ML; Pérez S; Beaujouan JC; Jabourian M; Soubrié P; Glowinski J
J Neurochem; 2003 Oct; 87(2):487-96. PubMed ID: 14511126
[TBL] [Abstract][Full Text] [Related]
10. Effect of scyliorhinin I and synthetic scyliorhinin I derivatives at mammalian tachykinin NK1, NK2 and NK3 receptors.
Patacchini R; Quartara L; Rolka K; Zboinska J; Kupryszewski G; Maggi CA
Eur J Pharmacol; 1993 Dec; 250(2):311-6. PubMed ID: 7509285
[TBL] [Abstract][Full Text] [Related]
11. Centrally administered hemokinin-1 (HK-1), a neurokinin NK1 receptor agonist, produces substance P-like behavioral effects in mice and gerbils.
Duffy RA; Hedrick JA; Randolph G; Morgan CA; Cohen-Williams ME; Vassileva G; Lachowicz JE; Laverty M; Maguire M; Shan LS; Gustafson E; Varty GB
Neuropharmacology; 2003 Aug; 45(2):242-50. PubMed ID: 12842130
[TBL] [Abstract][Full Text] [Related]
12. Comparison of tachykinin NK1 and NK2 receptors in the circular muscle of the guinea-pig ileum and proximal colon.
Maggi CA; Patacchini R; Meini S; Quartara L; Sisto A; Potier E; Giuliani S; Giachetti A
Br J Pharmacol; 1994 May; 112(1):150-60. PubMed ID: 7518302
[TBL] [Abstract][Full Text] [Related]
13. Central tachykinin NK3 receptors in the inhibitory action on the rat colonic propulsion of a new tachykinin, PG-KII.
Broccardo M; Improta G; Tabacco A
Eur J Pharmacol; 1999 Jul; 376(1-2):67-71. PubMed ID: 10440091
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.
Picard P; Regoli D; Couture R
Br J Pharmacol; 1994 May; 112(1):240-9. PubMed ID: 7518304
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporin A is a substance P (tachykinin NK1) receptor antagonist.
Gitter BD; Waters DC; Threlkeld PG; Lovelace AM; Matsumoto K; Bruns RF
Eur J Pharmacol; 1995 May; 289(3):439-46. PubMed ID: 7556412
[TBL] [Abstract][Full Text] [Related]
16. Neurokinin receptors in drug and alcohol addiction.
Schank JR
Brain Res; 2020 May; 1734():146729. PubMed ID: 32067964
[TBL] [Abstract][Full Text] [Related]
17. Emerging targets for cough therapies; NK1 receptor antagonists.
Badri H; Smith JA
Pulm Pharmacol Ther; 2019 Dec; 59():101853. PubMed ID: 31622673
[TBL] [Abstract][Full Text] [Related]
18. Tachykinin receptors in the guinea-pig renal pelvis: activation by exogenous and endogenous tachykinins.
Maggi CA; Patacchini R; Eglezos A; Quartara L; Giuliani S; Giachetti A
Br J Pharmacol; 1992 Sep; 107(1):27-33. PubMed ID: 1384907
[TBL] [Abstract][Full Text] [Related]
19. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation.
Quartara L; Maggi CA
Neuropeptides; 1997 Dec; 31(6):537-63. PubMed ID: 9574822
[TBL] [Abstract][Full Text] [Related]
20. Functional characterisation of tachykinin receptors mediating ion transport in porcine jejunum.
Thorbøll JE; Bindslev N; Hansen MB; Schmidt P; Skadhauge E
Eur J Pharmacol; 1998 Oct; 359(2-3):271-9. PubMed ID: 9832399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
